World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0010600394
Reproduction Date:

Title: Carisbamate  
Author: World Heritage Encyclopedia
Language: English
Subject: Styramate, CP-615,003, Heptobarbital, Nealbarbital, CGS-8216
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
CAS number  YesY
ATC code N03
ChemSpider  YesY
Chemical data
Formula C9H10ClNO3 
Mol. mass 215.633 g/mol

Carisbamate (YKP 509, proposed trade name Comfyde) is an experimental anticonvulsant drug under development by Johnson & Johnson Pharmaceutical Research and Development. In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division of SK Holdings), a South Korean company. A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Its mechanism of action is unknown.[1][2]

On October 24, 2008, Johnson & Johnson announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for carisbamate.[3] Carisbamate has received provisional approval by the FDA to be marketed under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.

A double-blind, placebo-controlled trial cf carisbamate in 323 patients with migraine failed to demonstrate that the active drug was more effective than placebo.[4] However, carisbamate was well tolerated at doses up to 600 mg/day.


  1. ^ Rogawski MA (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res 69 (3): 273–294.  
  2. ^ Novak GP, Kelley M, Zannikos P, Klein B (2007). "Carisbamate (RWJ-333369)". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 4 (1): 106–109.  
  3. ^ "Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate" (Press release). Johnson & Johnson. 2008-10-24. Retrieved 2008-11-02. 
  4. ^ Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group. (2009). "Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial". Headache 49 (2): 216–226.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.